IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
IGC Pharma, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 103.38M shares outstanding
USIGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness.
It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development.
In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research.
The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.
Leadership
Claudia Grimaldi
Vice President, Principal Financial Officer, Chief Compliance Officer & Non-Independent Director
Ram Mukunda
Founder, President, Chief Executive Officer & Director
Benysh Qureshi
Director of Operations
Rohit Goel
Director of Accounting & Senior Director
Employees
67
Country
US
Sector
Healthcare
Website
igcpharma.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 GRIMALDI CLAUDIA | PFO | Withholding/Transfer | 150.0K | -- | Sep 25, 2026 |
 Mukunda Ram | CEO | Withholding/Transfer | 100.0K | -- | Sep 25, 2026 |
| Mukunda Ram | CEO | Withholding/Transfer | 100.0K | -- | Sep 25, 2026 |
| Mukunda Ram | CEO | Grant/Award | 2.23M | $601.1K | Jun 30, 2026 |
| GRIMALDI CLAUDIA | PFO | Grant/Award | 2.05M | $553.1K | Jun 30, 2026 |
 Moran James P | Director | Option Exercise | 50.0K | -- | Apr 1, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Bradbury Strategic Investment Fund A · may incl. warrants· stale · filed Aug 2024 | 13.8M | 13.4% | 13D |
 Mukunda Ram CEO, Director | 6.7M | 6.5% | FORM 4 |
 GRIMALDI CLAUDIA PFO, Director | 3.3M | 3.2% | FORM 4 |
 PRINS RICHARD K Director | 1.5M | 1.5% | FORM 4 |
 Moran James P Director | 1.2M | 1.2% | FORM 4 |
GEODE CAPITAL MANAGEMENT, LLC | 879.4K | 0.9% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 814.9K | 0.8% | 13F |
BlackRock, Inc. | 703.8K | 0.7% | 13F |
AdvisorShares Investments LLC | 678.5K | 0.7% | 13F |
CITADEL ADVISORS LLC | 437.3K | 0.4% | 13F |
Insiders
- GRIMALDI CLAUDIAPFO
- Mukunda RamCEO
- Moran James PDirector
- PRINS RICHARD KDirector
- LIERMAN TERRY LDirector
based on 103.38M shares outstanding
US30d Avg
559.49K
60d Avg
570.88K
90d Avg
732.28K